左旋门冬酰胺酶合并剂量应用的疗效观察及成本分析  

Curative effect observation and cost analysis for therapy with L-asparaginase(L-Asp)at meige dosage

作　　者：王君霞[1] 戴永利[1] 黄费祥[1] 罗德春[1] 周少宏[1] 郭林梅[1] 

机构地区：[1]兰州军区兰州总医院儿科,730050

出　　处：《中国小儿血液与肿瘤杂志》2006年第2期76-78,共3页Journal of China Pediatric Blood and Cancer

基　　金：甘肃省自然科学基金(ZS021-A25-093-Y)

摘　　要：目的分析在急性淋巴细胞白血病患儿中并量应用左旋门冬酰胺酶(L-Asp)后的疗效、副反应及治疗费用,以探讨有效、经济的治疗措施。方法在应用L-Asp的化疗方案中,将L-Asp总量以整支为计量单位,隔日或隔两日应用。结果合并剂量应用后,L-Asp的单药治疗费用较未并量应用时减少30-40%。并量应用L-Asp其诱导缓解率达100%。停药的9例病人中,无病生存分别为5、3、2年。结论并量应用L-Asp的ALL患儿诱导缓解率高,副反应少。无复发病例。总治疗成本明显下降。Objective In order to investigate an effective and economical therapy, the analyzes the curative effect, side - effect and cost in the therapy for L - asparaginase（ L - Asp） at meige dosage in childhood acute lymphocytic leukemia（ALL）. Method In using L -Asp regimen chemotherapy, we injected the meige dosage of L - Asp with single package at every other day or two other days. Results After using L- Asp in meige dosage, the cost of single medicine treatment has reduced 30 -40%, compared to the treatment without meige dosage. And the rate of induced remission is as high as 100%. Among nine patients who ceased the therapy, their disease -free survival（DFS） were 5,3 and 2 years. Conclusion The therapy for L - Asp at meige dosage in childhood ALL have been approved that the induced remission rate is higher, side -effect is lower. We also have confirmed that all of the patients using that therapy never relapsed , and their whole cost of therapy descended apparently

关 键 词：急性淋巴细胞白血病 左旋门冬酰胺酶 合并剂量 

分 类 号：R733.71[医药卫生—肿瘤] R1[医药卫生—临床医学]